The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study
Launched by UNIVERSITY OF MICHIGAN · Oct 6, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The CAPACHINOS-2 Study is looking at how caffeine might help patients recover better after major surgery. Researchers want to see if giving caffeine can reduce the chances of developing postoperative delirium, which is a condition affecting mental clarity and awareness after surgery. This study is currently recruiting participants who are 70 years or older and are scheduled for specific types of surgeries that require general anesthesia and will involve a hospital stay of at least 48 hours.
To be eligible for this study, participants must be adults who are able to provide informed consent and are willing to follow the study procedures. However, there are some exclusions, such as those undergoing emergency surgery, individuals with severe cognitive issues, or those who cannot tolerate caffeine. If you join the study, you will receive caffeine during your recovery period, and researchers will monitor your mental and overall health to gather important data about the effects of caffeine on recovery after surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adult (\>/= 70 years old) undergoing non-cardiac, non-intracranial neurologic, non-major vascular surgery requiring general anesthesia with a planned admission for at least 48 hours.
- • 2. Stated willingness to comply with all study procedures and availability for the duration of the study.
- • 3. Provision of signed and dated informed consent form.
- Exclusion Criteria:
- • 1. Emergency surgery
- • 2. Outpatient surgery
- • 3. Severe cognitive impairment precluding the capacity for informed consent
- • 4. Seizure disorder history
- • 5. Intolerance or allergy to caffeine (based on subjective reporting or objective documentation)
- • 6. Weight \>130 kg (as a 3 mg/kg dose would approach the upper limit of daily intake recommended by the FDA)
- • 7. Enrollment in conflicting research study
- • 8. Patients in acute liver failure
- • 9. Acute kidney injury preoperatively
- • 10. Diagnosis of pheochromocytoma
- • 11. Severe audiovisual impairment
- • 12. Non-English speaking
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
Phillip Vlisides, MD
Principal Investigator
Assistant Professor of Anesthesiology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials